Transgene

[Gillepils]

Moet toegeven dat ik er mij ook wel aan stoor. Mocht de koers dan nog omhoog gaan ok maar triestig koersverloop de laatste tijd.

Tja, Galapagos gaat ook niets vooruit. Geduldig laten rijpen.

[Stofke]

Moet toegeven dat ik er mij ook wel aan stoor. Mocht de koers dan nog omhoog gaan ok maar triestig koersverloop de laatste tijd.

Tja, Galapagos gaat ook niets vooruit. Geduldig laten rijpen.

Gelukkig gaat mijn Pharnext nog wat vooruit

[ancaoli]

Moet toegeven dat ik er mij ook wel aan stoor. Mocht de koers dan nog omhoog gaan ok maar triestig koersverloop de laatste tijd.

Tja, Galapagos gaat ook niets vooruit. Geduldig laten rijpen.

Gelukkig gaat mijn Pharnext nog wat vooruit

Euh vooruit, vandaag wel -3%
Deze voormiddag was het wel feest, volatiel aandeeltje.

[Stofke]

Moet toegeven dat ik er mij ook wel aan stoor. Mocht de koers dan nog omhoog gaan ok maar triestig koersverloop de laatste tijd.

Tja, Galapagos gaat ook niets vooruit. Geduldig laten rijpen.

Gelukkig gaat mijn Pharnext nog wat vooruit

Euh vooruit, vandaag wel -3%
Deze voormiddag was het wel feest, volatiel aandeeltje.

We komen van 9 euro in december, die 3% daling doet niet echt pijn dan. Idd volatiel door de heel weinige free float.

[Luz]

Transgene to start clinical development of lead myvacTM individualized immunotherapy, TG4050, in 2019, under its partnership with NEC

Published: Mar 05, 2019

STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces its decision to initiate clinical developments of its lead myvacTM candidate, TG4050, and the finalization of its collaboration agreement with NEC. This product is designed and manufactured by Transgene using its proprietary platform myvacTM (*1) and integrating neoantigens selected by NEC’s Neoantigen Prediction System (*2).

TG4050 capitalizes on the tremendous progress in the field of artificial intelligence (AI) and on advances in genome sequencing to create an individualized immunotherapy, targeted to mutated antigens identified by sequencing and predicted to be relevant target by the NEC’s algorithm.

Transgene will be responsible for the clinical development and will sponsor two clinical studies starting in H2 2019:

A study in ovarian cancer patients after first line surgery and chemotherapy
A study in head and neck cancer patient after surgery and radiation therapy.
These studies, which will be co-financed by Transgene and NEC, will evaluate safety and immunogenicity of TG4050 and, pave the way for combination studies with different classes of therapies.

“Individualized vaccination is being increasingly perceived as a promising therapeutic modality to specifically activate the immune system to attack tumor cells. We are pleased, together with NEC, to be advancing in the clinic TG4050 in H2 2019. We are confident that this approach has the potential to transform the treatment of a broad range of solid tumors,” said Éric Quéméneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer of Transgene.

“Individualized immunotherapy is a breakthrough science which holds great promises to achieve clinical benefits for cancer patients. We are honored to partner with Transgene in the initiation of these clinical trials this year. The success of this product would create immense impact that could improve the quality of life for many cancer patients”, commented Osamu Fujikawa, Senior Vice President, Business Innovation Unit, of NEC Corporation.

[And its gone!]

Nieuws op komst? +4% zonder pb.

[Stofke]

Transgene $TNG - NEOVIVA Project Supporting the Development of myvac™ Awarded a €5.2 Million Grant from Bpifrance’s “Investments for the Future” Programme

[And its gone!]

BRIEF-Transgene Announces NEOVIVA Project Is Awarded A Grant Of 5.2 Million Euros
17:49 (13/03) - Bron: Reuters

March 13 (Reuters) - TRANSGENE SA TRNG.PA :
* TRANSGENE - NEOVIVA PROJECT SUPPORTING THE DEVELOPMENT OF
MYVAC™
AWARDED A €5.2 MILLION GRANT FROM BPIFRANCE’S “INVESTMENTS FOR
THE FUTURE” PROGRAMME
* NEOVIVA PROJECT WILL RECEIVE EUR 5.2 MILLION OVER
FIVE-YEAR
DURATION OF PROGRAM FROM BPIFRANCE, OF WHICH TRANSGENE WILL
RECEIVE EUR 2.6 MILLION
* TWO PROOF OF CONCEPT CLINICAL TRIALS ARE BEING PREPARED IN
EUROPE AND US FOR TREATMENT OF HPV-NEGATIVE HEAD AND NECK
CANCERS AND OVARIAN CANCER
* THESE ARE EXPECTED TO START IN H2 2019

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))

[And its gone!]

March 18, 2019 - Transgene secures a €20 Million Revolving Credit Facility with Natixis

https://www.transgene.fr/wp-content/uploads/2019/03/20190318-PR-Natixis-loan-EN.pdf

BRIEF-Transgene Secures A 20 Million Euros Revolving Credit Facility With Natixis
18:08 (18/03) - Bron: Reuters

March 18 (Reuters) - TRANSGENE SA TRNG.PA :
* TRANSGENE SECURES A €20 MILLION REVOLVING CREDIT FACILITY
WITH
NATIXIS
* CREDIT FACILITY WILL HAVE A 30-MONTH TERM AND TRANSGENE
WILL BE
ABLE TO DRAW ON AND REPAY FACILITY AT ITS DISCRETION
* CEO: "WITH THIS NEW LOAN FACILITY, WE NOW HAVE FUNDS
NEEDED TO
SUPPORT OUR CLINICAL AND PRE-CLINICAL ACTIVITIES UNTIL MID-2020"

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))

[And its gone!]

BRIEF-Transgene FY Net Result Turns To Profit Of 8.0 Million Euros
17:55 (20/03) - Bron: Reuters

March 20 (Reuters) - TRANSGENE SA TRNG.PA :
* FY NET RESULT EUR 8.0 MILLION VERSUS LOSS OF EUR 32.3
MILLION
YEAR AGO
* FY OPERATING INCOME EUR 43 MILLION VERSUS EUR 8.1 MILLION
YEAR
AGO
* CASH POSITION AT YEAR END EUR 17 MILLION VERSUS EUR 41.4
MILLION
YEAR AGO

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))

Transgene: A positive 2018, moving ahead with a strong portfolio
✓ Clinical trials set to announce key data in 2019
✓ Invir.IO™ platform designed to deliver a new generation of oncolytic viruses has demonstrated promising preclinical data and is progressing to clinical stage
✓ Launch of myvacTM - our platform for highly innovative virus-based, individualized immunotherapy has already achieved multiple milestones translated into a strategic partnership with NEC
✓ Received $48 million in Tasly Biopharmaceuticals Co., Ltd. (‘Tasly’) shares through the sale of TG1050 and TG6002 rights to Tasly in Greater China
✓ Key financial elements:
o €8 million in net income in 2018 as a result of the Tasly deal
o €20 million revolving credit facility secured, using its Tasly shares as collateral
o Financial visibility extended until mid-2020

https://www.transgene.fr/wp-content/upl ... S-EN-2.pdf